作为潜在的预后指标和治疗目标,LSM4是三阴性乳腺癌进展的潜在预后指标和治疗目标
Zhen Ren1, Yifan Li2, Xiaobing Yang3
1Department of Critical Care Medicine, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Gland surgery
|November 12, 2025
概括
LSM4基因通过AKT/PI3K通路增强细胞增殖,迁移和入侵,促进三阴性乳腺癌 (TNBC) 的进展. 这项研究强调LSM4作为TNBC的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- LSM4在三阴性乳腺癌 (TNBC) 进展中的作用在很大程度上是未知的.
- LSM4 是 LSM (Like-Sm) 基因家族的一员.
研究的目的:
- 研究LSM4在TNBC进展中的机制性作用.
- 评估LSM4作为TNBC中的预后指标.
主要方法:
- 生物信息学分析,包括单变量/多变量Cox和名ogram模型.
- 基因本体学 (GO) 路径分析.
- 实验验证使用西部涂抹,qPCR,免疫光,流细胞计,透井测定和救援实验.
主要成果:
- 与正常样本相比,TNBC样本中的LSM4表达显著增加.
- LSM4促进了TNBC细胞的增殖,迁移和入侵.
- LSM4通过AKT/PI3K信号通路和ECT2.2调节TNBC细胞迁移和入侵.
结论:
- 在TNBC的进展中,LSM4起着至关重要的作用.
- LSM4是TNBC的一个潜在的治疗点.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:39lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K